Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Lesley J, Fallowfield"'
Publikováno v:
Psycho-oncology. 22(12)
Decisions about adjuvant chemotherapy in older women with early stage breast cancer (EBC) are often challenging. Uncertainty about benefits due to limited data about treatment efficacy and outcomes complicates decision making. This qualitative study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f3c78a5e058cb5853db0846cc1bb1a42
https://pubmed.ncbi.nlm.nih.gov/23813806
https://pubmed.ncbi.nlm.nih.gov/23813806
Autor:
Lesley J, Fallowfield
Publikováno v:
BMJ (Clinical research ed.). 343
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a40fcb0d4a70354c212467e556d20599
https://pubmed.ncbi.nlm.nih.gov/22108271
https://pubmed.ncbi.nlm.nih.gov/22108271
Publikováno v:
Journal of evaluation in clinical practice. 17(1)
High-grade glioma profoundly affects patients and their families. The best ongoing care for patients completing radical treatment is uncertain. To address this issue a UK-wide audit surveying the follow-up practices of multidisciplinary cancer teams
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c9ed0637216551f642d772748174d965
https://pubmed.ncbi.nlm.nih.gov/21143347
https://pubmed.ncbi.nlm.nih.gov/21143347
Autor:
Fatima, Cardoso, Philippe L, Bedard, Eric P, Winer, Olivia, Pagani, Elzbieta, Senkus-Konefka, Lesley J, Fallowfield, Stella, Kyriakides, Alberto, Costa, Tanja, Cufer, Kathy S, Albain, M, Colleoni
Publikováno v:
JNCI Journal of the National Cancer Institute
Journal of the National Cancer Institute, 101(17), 1174-1181. Oxford University Press
Journal of the National Cancer Institute, 101(17), 1174-1181. Oxford University Press
Compared with treatment options for early-stage breast cancer, few data exist regarding the optimal use of chemotherapy for metastatic breast cancer (MBC). The choice of using a combination of cytotoxic chemotherapies vs sequential single agents is c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e194cb2e4b46fd939bb28cd4ccf65aff
http://hdl.handle.net/11573/1311180
http://hdl.handle.net/11573/1311180
Autor:
R Charles, Coombes, Emma, Hall, Lorna J, Gibson, Robert, Paridaens, Jacek, Jassem, Thierry, Delozier, Stephen E, Jones, Isabel, Alvarez, Gianfilippo, Bertelli, Olaf, Ortmann, Alan S, Coates, Emilio, Bajetta, David, Dodwell, Robert E, Coleman, Lesley J, Fallowfield, Elizabeth, Mickiewicz, Jorn, Andersen, Per E, Lønning, Giorgio, Cocconi, Alan, Stewart, Nick, Stuart, Claire F, Snowdon, Marina, Carpentieri, Giorgio, Massimini, Judith M, Bliss, Cornelius, van de Velde
Publikováno v:
The New England journal of medicine. 350(11)
background Tamoxifen, taken for five years, is the standard adjuvant treatment for postmenopausal women with primary, estrogen-receptor–positive breast cancer. Despite this treatment, however, some patients have a relapse. methods We conducted a do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1cc1ebe5ba8c582fbca5b9de097a317
https://pubmed.ncbi.nlm.nih.gov/15237463
https://pubmed.ncbi.nlm.nih.gov/15237463